Phio Pharmaceuticals Corp. PHIO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Phio Pharmaceuticals Corp. (PHIO) is a healthcare company listed in the US with a market value of about $9M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -87%.
About Phio Pharmaceuticals
Phio Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $34000 in 2015 to $21000 in 2019, a decline of about 11.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 4638% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $21000 | $138000 | $15000 | $19000 |
| Net income | -$9M | -$7M | -$11M | -$11M | -$13M | -$9M | -$9M | -$7M | -$12M | -$9M |
| Free cash flow | -$8M | -$7M | -$11M | -$12M | -$12M | -$9M | -$9M | -$8M | -$10M | -$8M |
| EPS (diluted) | $-1.45 | $-9.08 | $-46.76 | $-90.90 | $-111.87 | $-17.28 | $-173.97 | $-517.14 | $-2732.41 | $-8122.99 |
| Net margin | — | — | — | — | — | — | -42419.0% | -5333.3% | -83013.3% | -47336.8% |
| ROIC | -36.1% | -123.6% | -110.1% | -104.1% | -60.8% | -64.4% | -143.4% | -54.1% | -678.8% | -83.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Phio Pharmaceuticals pay a dividend?
Not currently.
Is Phio Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Phio Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.